Université Libre de Bruxelles

Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes

a month ago

• Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment. • Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden. • Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.

Novel Drug Shows Promise in Reducing Dermatomyositis Disease Activity

4 months ago

A phase II clinical trial has demonstrated that dazukibart, an investigational monoclonal antibody targeting interferon beta (IFNβ), significantly reduces disease activity in adults with dermatomyositis. The study highlights the drug's potential as a targeted therapy for this chronic autoimmune disease, with notable improvements in skin symptoms and quality of life for patients.

Pelareorep Plus Paclitaxel Shows Survival Benefit in HR+/HER2- Breast Cancer

8 months ago

• The combination of pelareorep and paclitaxel demonstrated a significant improvement in overall survival (OS) compared to paclitaxel alone in patients with HR+/HER2- metastatic breast cancer. • In the BRACELET-1 trial, the median OS was not reached in the pelareorep/paclitaxel arm, while it was 18.2 months in the paclitaxel monotherapy arm (HR, 0.48). • The 2-year survival rate was 64% in the pelareorep/paclitaxel group versus 33% in the paclitaxel monotherapy group, indicating a substantial survival advantage. • Progression-free survival (PFS) also improved with the combination therapy, showing a median PFS of 12.1 months compared to 6.4 months with paclitaxel alone (HR, 0.39).

ESMO 2024: New Leadership and Groundbreaking Developments in Oncology Research and Patient Care

8 months ago

• ESMO President Prof Andres Cervantes highlights the organization's evolution into a comprehensive support network for oncologists, announcing new initiatives including AI & Digital Oncology Congress 2025. • Significant advances in oncofertility research reveal pregnancy after breast cancer is feasible, leading to new fertility preservation laws and guidelines for cancer patients. • Whole Genome Sequencing emerges as a transformative tool in personalized cancer care, with Prof Serena Nik-Zainal demonstrating its potential for identifying unique mutational signatures in individual tumors.